BRIGHENTI, Matteo
BRIGHENTI, Matteo
A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer
2007-01-01 Dalla Chiesa, M.; Buti, S.; Tomasello, G.; Negri, F.; Buononato, M.; Brunelli, A.; Lazzarelli, S.; Brighenti, M.; Donati, G.; Passalacqua, R.
Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen
2010-01-01 Tomasello, G.; Chiesa, M. D.; Buti, S.; Brighenti, M.; Negri, F.; Rovere, R. K.; Martinotti, M.; Buononato, M.; Brunelli, A.; Lazzarelli, S.; Donati, G.; Passalacqua, R.
Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy
2014-01-01 Bersanelli, M.; Buti, S.; Camisa, R.; Brighenti, M.; Lazzarelli, S.; Mazza, G.; Passalacqua, R.
Immunotherapy options in metastatic renal cell cancer: Where we are and where we are going
2006-01-01 Passalacqua, R.; Buti, S.; Tomasello, G.; Longarini, R.; Brighenti, M.; Dalla Chiesa, M.
Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: The GOIRC-AIFA FARM6PMFJM trial
2017-01-01 Tiseo, Marcello; Boni, Luca; Ambrosio, Francesca; Camerini, Andrea; Baldini, Editta; Cinieri, Saverio; Brighenti, Matteo; Zanelli, Francesca; Defraia, Efisio; Chiari, Rita; Dazzi, Claudio; Tibaldi, Carmelo; Turolla, Gianni Michele; D'Alessandro, Vito; Zilembo, Nicoletta; Trolese, Anna Rita; Grossi, Francesco; Riccardi, Ferdinando; Ardizzoni, Andrea
Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: A case report
2007-01-01 Buti, S.; Ricco, M.; Chiesa, M. D.; Copercini, B.; Tomasello, G.; Brighenti, M.; Passalacqua, R.
Patient performance status and cancer immunotherapy efficacy: a meta-analysis
2018-01-01 Bersanelli, M.; Brighenti, M.; Buti, S.; Barni, S.; Petrelli, F.
Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: Results of a phase II trial
2011-01-01 Dalla Chiesa, M.; Tomasello, G.; Buti, S.; Rovere, R. K.; Brighenti, M.; Lazzarelli, S.; Donati, G.; Passalacqua, R.
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer | 1-gen-2007 | Dalla Chiesa, M.; Buti, S.; Tomasello, G.; Negri, F.; Buononato, M.; Brunelli, A.; Lazzarelli, S.; Brighenti, M.; Donati, G.; Passalacqua, R. | |
Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen | 1-gen-2010 | Tomasello, G.; Chiesa, M. D.; Buti, S.; Brighenti, M.; Negri, F.; Rovere, R. K.; Martinotti, M.; Buononato, M.; Brunelli, A.; Lazzarelli, S.; Donati, G.; Passalacqua, R. | |
Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy | 1-gen-2014 | Bersanelli, M.; Buti, S.; Camisa, R.; Brighenti, M.; Lazzarelli, S.; Mazza, G.; Passalacqua, R. | |
Immunotherapy options in metastatic renal cell cancer: Where we are and where we are going | 1-gen-2006 | Passalacqua, R.; Buti, S.; Tomasello, G.; Longarini, R.; Brighenti, M.; Dalla Chiesa, M. | |
Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: The GOIRC-AIFA FARM6PMFJM trial | 1-gen-2017 | Tiseo, Marcello; Boni, Luca; Ambrosio, Francesca; Camerini, Andrea; Baldini, Editta; Cinieri, Saverio; Brighenti, Matteo; Zanelli, Francesca; Defraia, Efisio; Chiari, Rita; Dazzi, Claudio; Tibaldi, Carmelo; Turolla, Gianni Michele; D'Alessandro, Vito; Zilembo, Nicoletta; Trolese, Anna Rita; Grossi, Francesco; Riccardi, Ferdinando; Ardizzoni, Andrea | |
Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: A case report | 1-gen-2007 | Buti, S.; Ricco, M.; Chiesa, M. D.; Copercini, B.; Tomasello, G.; Brighenti, M.; Passalacqua, R. | |
Patient performance status and cancer immunotherapy efficacy: a meta-analysis | 1-gen-2018 | Bersanelli, M.; Brighenti, M.; Buti, S.; Barni, S.; Petrelli, F. | |
Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: Results of a phase II trial | 1-gen-2011 | Dalla Chiesa, M.; Tomasello, G.; Buti, S.; Rovere, R. K.; Brighenti, M.; Lazzarelli, S.; Donati, G.; Passalacqua, R. |